First trimester screening and progesterone levels in HIV positive women under HAART therapy

Ginekol Pol. 2021 Apr 29. doi: 10.5603/GP.a2021.0096. Online ahead of print.

Abstract

Objectives: HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease. Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.

Material and methods: It was a prospective study that took place between January 2017- December 2019 in "Cuza-Vodă" Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.

Results: Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.

Discussion: These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.

Conclusions: Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.

Keywords: AIDS; HIV; antiretroviral therapy; pregnancy.